OIG Guidance and Reports
Nolan Auerbach & White’s healthcare fraud whistleblower attorneys provide experienced representation under the qui tam provisions of the False Claims Act. Our qui tam attorneys file Medicare fraud and other Healthcare fraud qui tam lawsuits for our clients, drawing on a wealth of experience and resources. The following are relevant OIG Compliance Guidance and Reports related to the areas in which our qui tam attorneys focus:
HHS OIG publishes a work plan each year that highlights both old and new areas of potential fraud. These constitute a summary of various OIG work plan reviews for various U.S. Department of Health and Human Services programs and operations with the specific goal of detecting and eliminating fraud, waste, and abuse.
This Compliance Program Guidance for Nursing Facilities was developed by the Office of Inspector General (OIG). The OIG has previously developed and published compliance program guidance focused on several other areas and aspects of the health care industry. The development and issuance of this compliance program guidance for nursing facilities was intended to serve as a positive step toward reducing violations of the False Claims Act and promoting a higher level of ethical and lawful conduct throughout the entire healthcare industry.
This Compliance Program Guidance for Ambulance Suppliers was developed by the Office of Inspector General (OIG). The OIG has previously developed and published voluntary compliance program guidance focused on several different areas of the healthcare industry. This voluntary compliance program guidance was intended to assist ambulance suppliers and other health care providers in developing their own strategies for complying with federal healthcare program requirements and preventing false claim act violations.
This Federal Register notice sets forth the Compliance Program Guidance for Pharmaceutical Manufacturers was developed by the Office of Inspector General (OIG). Through this notice, the OIG is setting forth its general views on the value and fundamental principles of compliance programs for pharmaceutical manufacturers and the specific elements that pharmaceutical manufacturers should consider when developing and implementing an effective compliance program. The guidance overviews most areas of Pharmaceutical fraud.
This OIG Report had 2 Objectives:
(1) To determine whether all State Medicaid agencies collect drug manufacturer rebates for all physician-administered drugs; and
(2) To estimate the potential savings that would result if all State Medicaid agencies collected drug manufacturer rebates for physician-administered drugs.